Canada


Year
November 20, 2013
Mississauga, ON– Genzyme, a Sanofi company, announced today that Health Canada has approved AUBAGIO® (teriflunomide) 14 mg as monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
Last Updated: 12/3/2015
Contact

Genzyme Canada
Canadian Office 
2700 Matheson Blvd. East 
West Tower, Suite 800 
Mississauga, Ontario L4W 4V9 
Canada 
Tel: +1 905 625 0011 
Fax: +1 905 625 7811 
Toll Free: +1 877 220 8918 
Email

Genzyme Medical Information 
Tel: +1 800 589 6215
Email

If this is an emergency, please contact your local emergency department.

Ethics inquiries 
Tel: +1 800 648 1297

This Is Genzyme
Discover more about Genzyme's purpose, legacy, and innovation in our corporate brochure.

Careers
Explore opportunities at a company that's as committed to our employees as we are to our patients.

infoBox